Beta Capital

About

Beta Capital is a New York-based seed fund investing at the intersection of artificial intelligence and regulated industries. Founded in 2020 by Maria Chen and Samuel Park, the firm manages $120M across its debut fund and a recently closed Fund II ¹. Beta Capital focuses exclusively on seed-stage companies, writing checks between $1M and $3M, and typically targets ownership of 8-12% at entry ².

The firm differentiates itself through deep industry networks in healthcare and energy. Both founding partners previously held operating roles – Chen as VP of Product at a digital health company and Park as a climate-tech founder ³. Beta Capital runs a “Regulatory Navigator” program that connects portfolio companies with former regulators and policy experts ¹.

Stated Thesis

Beta Capital’s public thesis centers on “AI-native companies tackling problems in industries where trust, safety, and compliance are table stakes” ¹. Their investment page outlines three verticals:

1. AI + Healthcare – diagnostic tools, clinical workflow automation, and drug discovery platforms.
2. AI + Climate – carbon accounting, grid optimization, and supply chain decarbonization.
3. AI + Financial services – compliance automation, fraud detection, and risk modeling.

Maria Chen has described their approach as “looking for founders who understand that in regulated markets, the regulatory moat is the business model” ⁴.

Inferred Thesis

Based on analysis of their 18 known portfolio investments:

• 44% healthcare and biotech AI
• 28% climate-tech and energy AI
• 17% fintech and compliance AI
• 11% other applied AI

Notable patterns:

• 100% of portfolio companies incorporate machine learning or AI as a core product component
• 72% of founding teams include at least one person with direct domain experience in the target industry (not just tech experience) ²
• 56% of investments were in companies with a regulatory or compliance angle
• 39% of portfolio companies had previously gone through an accelerator (Y Combinator, Techstars, or similar)
• Average check size: $1.8M
• Median pre-money valuation at seed: $15M

Beta Capital appears to avoid pure consumer AI plays and has no known investments in social media, gaming, or content generation.

Portfolio

In Their Own Words

“Everyone is investing in AI. We invest in AI where getting it wrong has consequences – where the output has to be explainable, auditable, and defensible. That constraint is what creates durable businesses.” – Maria Chen, General Partner, at HealthTech Summit 2025 ⁴

“We ask every founder: what happens when your model is wrong? If they haven’t thought deeply about failure modes, they haven’t thought deeply enough about their market.” – Samuel Park, General Partner, interview with AI Insider ⁵

“Domain expertise is not optional in our portfolio. We’ve passed on brilliant ML teams because they didn’t have anyone who had actually worked in the industry they were trying to disrupt.” – Maria Chen, on the Seed to Scale podcast ⁶

What Founders Say

“Maria understood our FDA strategy better than most healthcare-focused investors. She had been through the 510(k) process at her previous company and knew exactly which questions to ask.” – Dr. Ravi Anand, CEO of Cardiax ⁷

“Beta Capital’s regulatory network saved us at least a year. They connected us with a former FERC commissioner who helped us navigate utility procurement processes.” – Lena Johansson, CEO of GridMind ⁸

“They’re not the flashiest name on a cap table, but they are the most useful. Every month, Samuel sends a curated list of potential design partners. Half our pilot customers came from those intros.” – Kevin Wu, CTO of CompliBot ⁹

“What I appreciated most was that they said no to the things outside their expertise. When we needed help with consumer marketing, Maria said ‘that’s not us’ and introduced us to someone who could actually help.” – Dr. Fatima Al-Rashid, CEO of MolecuLab ¹⁰

Sources